Scientists Just Found a Mushroom That Carries Both Psilocybin and a Liver-Killing Toxin. Foraging by Guesswork Is Over.

Andrew Kunik was an undergraduate documenting fungi at the University of Florida’s Ordway-Swisher Biological Station when he picked up a mushroom that, by every visible measure, was nothing special. It was, in the words of the team that later studied it, “small and brown, like hundreds of other mushroom species,” hard to tell apart from its neighbors “even for a trained expert.” It had been documented only a handful of times anywhere in the world. When the lab ran its chemistry, they found something no one had confirmed in a single mushroom before: psilocybin, the compound that makes “magic mushrooms” magic, sitting alongside amatoxins, the compounds responsible for most fatal mushroom poisonings.

If you are picking your own mushrooms by how they look, you are now gambling with your liver, and this week science proved the dice are loaded.

The paper, by Kunik, Matthew E. Smith, Jason Slot, and colleagues, published November 11 in Current Biology. They nicknamed the species, Galerina indica, the “dark magic mushroom.” It is today’s psychedelics spotlight because it lands in the same week the federal government started paying scientists to study people who take mushrooms at home, and those two facts belong together.

A mushroom that blurs the one line foragers rely on

The tired advice to people who pick wild mushrooms is to learn the deadly ones and avoid them. That advice assumes a clean split: there are psychedelic mushrooms over here, poisonous mushrooms over there, and if you know the difference you are fine. Galerina indica breaks that assumption. The genus Galerina was already known for some species that carry amatoxins. Finding psilocybin in one of them means a mushroom could, in principle, pass a home test for “is this psychoactive?” and still be the thing that kills you. The researchers traced how this happened: the genes for both compounds appear to have entered the genus through two separate events in which DNA jumped between unrelated organisms. “Two independent horizontal gene transfer events for these specialized metabolites in one mushroom genus are unheard of,” Bryn Dentinger said in the University of Florida announcement.

Calibrate that properly. This is one rare species, found a handful of times, in a Florida research station. It is not a sign that the mushrooms in a dispensary bag or a friend’s grow tent are secretly laced with liver poison. Cultivated psilocybin mushrooms are a different situation from wild picking. The finding matters most for one group: people who forage, or who buy from someone who forages, and trust their eye.

Why amatoxin poisoning fools people

Here is the part that should change behavior. Amatoxin poisoning does not feel like poisoning at first. CDC’s 2016 report on a California cluster describes the course in three acts. For the first six to 24 hours after eating, nothing obvious happens. Then comes violent vomiting and diarrhea. Then, around a day or a day and a half in, people often feel better, and that is the trap. The toxin is still destroying liver cells the whole time, and full liver and organ failure tends to arrive around days three to five. CDC noted that people seen early are sometimes sent home, only to come back with a failing liver.

The numbers are not abstract. In a 2026 MMWR report on Amanita poisonings in Northern California between November 2025 and March 2026, CDC counted 39 cases. Thirty-two people recovered. Three needed new livers. Four died. Those were mostly death cap mushrooms, not psychedelic ones, but the biology of the toxin is the same, and the delay is what kills.

So, said plainly, because this is the thing worth holding onto: if you or someone you are with ate mushrooms and gets sick to the stomach many hours later, especially six or more, that is not a bad trip. That is an emergency. Go to an emergency room, say the word “mushrooms” out loud, and bring any leftover pieces. You can reach Poison Control at 1-800-222-1222 any hour for free. Feeling better the next day does not mean it is over.

Go to an emergency room, say the word “mushrooms” out loud, and bring any leftover pieces.

We built a culture of home foraging on a magazine story

None of this happens in a vacuum. On May 13, 1957, Life magazine ran a photo essay by a J.P. Morgan banker and amateur mycologist named R. Gordon Wasson about eating sacred mushrooms in a Mazatec village in Mexico. A Life editor, against Wasson’s wishes, titled it “Seeking the Magic Mushroom,” and the phrase never left. The essay introduced psychoactive mushrooms to a mass American audience, and a home-foraging culture grew up around them. The pattern that followed for sixty years was simple: law pushed psilocybin underground, so the knowledge about which mushroom was which traveled by word of mouth, forum posts, and guesswork rather than through any system built to keep people alive. Every forager who has ever squinted at a spore print and decided “close enough” is living inside the gap that prohibition made. Galerina indica is a reminder of what that gap costs.

Washington is now studying the kitchen, not just the clinic

The other psilocybin news this week points the same direction. At UCSF, Robin Carhart-Harris’s lab has launched the CANOPY Project, recruiting people who already plan to take psilocybin, LSD, ketamine, ayahuasca, ibogaine, or MDMA on their own, at home or at retreats, and following them with surveys for up to six months. Bay Area participants can get brain imaging and blood work before and after. It is one of three studies sharing $8.5 million from ARPA-H, the federal health research agency. “CANOPY gives us an opportunity to bring scientific rigor to these experiences at a scale we haven’t had before,” Carhart-Harris said. The study’s own page describes its aim as understanding real-world use to improve safety and well-being.

That is a quiet shift worth naming. Most of the psychedelic money of the last decade has gone into the clinic: Compass Pathways filed its psilocybin application for treatment-resistant depression with the FDA this month, joining Usona’s, and both describe a supervised session with a therapist, a controlled dose, and a manufactured drug. The kitchen-table version, where people are actually taking mushrooms right now, has been studied far less. A federal agency paying to learn what happens there is a recognition that the real-world use is not going to wait for the approved product.

For people in recovery, this is the part that hits close. We covered how the first psilocybin application landing at FDA is already stirring debate in recovery rooms, where some people see psychedelics as a lifeline and others see a relapse wearing a lab coat. Both camps should agree on this much: a drug you got from a stranger’s foraging trip is a different drug from the one in a trial, and you deserve to know which one you are holding.

What to actually do

If you are a provider, add mushrooms to the questions you ask about recent use, and ask where they came from: grown, bought, or picked. Make sure your front desk and triage staff know that stomach symptoms many hours after mushrooms should be treated as possible amatoxin poisoning, not sent home as a bad reaction. That one triage rule is the difference CDC keeps describing.

If you are someone who uses, or someone thinking about it: the safest mushroom is the one you did not pick yourself based on how it looked. Never eat a wild mushroom you cannot identify with certainty, and do not trust an app or a photo to do it for you. Keep the Poison Control number in your phone. For more on the whole class, our psychedelics and empathogens hub is updated as the FDA decisions come in, and our harm reduction desk covers the rest.

A small brown mushroom in a Florida research station did not change the risk of foraging. It just removed the last excuse for pretending the risk was about knowing what to look for.

It just removed the last excuse for pretending the risk was about knowing what to look for.